These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22120734)

  • 21. Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response.
    Arazi SS; Genvigir FD; Willrich MA; Hirata MH; Dorea EL; Bernik M; Hirata RD
    Clin Chim Acta; 2008 Jul; 393(2):119-24. PubMed ID: 18435918
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipid-lowering response to statins is affected by CYP3A5 polymorphism.
    Kivistö KT; Niemi M; Schaeffeler E; Pitkälä K; Tilvis R; Fromm MF; Schwab M; Eichelbaum M; Strandberg T
    Pharmacogenetics; 2004 Aug; 14(8):523-5. PubMed ID: 15284534
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transporter genes ABCG2 rs2231142 and ABCB1 rs1128503 polymorphisms and atorvastatin response in Chilean subjects.
    Prado Y; Zambrano T; Salazar LA
    J Clin Pharm Ther; 2018 Feb; 43(1):87-91. PubMed ID: 28833323
    [TBL] [Abstract][Full Text] [Related]  

  • 24. POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia.
    Drogari E; Ragia G; Mollaki V; Elens L; Van Schaik RH; Manolopoulos VG
    Pharmacogenomics; 2014 Dec; 15(16):1963-72. PubMed ID: 25521355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia.
    Ragia G; Kolovou V; Tavridou A; Elens L; Tselepis AD; Elisaf M; Van Schaik RH; Kolovou G; Manolopoulos VG
    Drug Metab Pers Ther; 2015 Mar; 30(1):43-8. PubMed ID: 25274942
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of atorvastatin on endothelial function in patients with familial hypercholesterolemia].
    Balakhonova TV; Pogorelova OA; Susekov AV; Kobylianskiĭ AG; Kuznetsova TV; Tvorogova MG; Masenko VP; Titov VN; Kukharchuk VV; At'kov OIu
    Kardiologiia; 2002; 42(1):15-21. PubMed ID: 12494218
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influence of SREBP-2 and SCAP gene polymorphisms on lipid-lowering response to atorvastatin in a cohort of Chilean subjects with Amerindian background.
    Lagos J; Zambrano T; Rosales A; Salazar LA
    Mol Diagn Ther; 2014 Aug; 18(4):435-43. PubMed ID: 24615250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
    Staatz CE; Goodman LK; Tett SE
    Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment.
    Rebecchi IM; Rodrigues AC; Arazi SS; Genvigir FD; Willrich MA; Hirata MH; Soares SA; Bertolami MC; Faludi AA; Bernik MM; Dorea EL; Dagli ML; Avanzo JL; Hirata RD
    Biochem Pharmacol; 2009 Jan; 77(1):66-75. PubMed ID: 18851956
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gender-Specific Association Between ABCC2 -24C>T SNP and Reduction in Triglycerides in Chilean Patients Treated With Atorvastatin.
    Prado Y; Arencibia A; Zambrano T; Salazar LA
    Basic Clin Pharmacol Toxicol; 2018 May; 122(5):517-522. PubMed ID: 29178257
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gender-specific effects of estrogen receptor alpha gene haplotype on high-density lipoprotein cholesterol response to atorvastatin: interaction with apolipoprotein AI gene polymorphism.
    Kajinami K; Brousseau ME; Lamon-Fava S; Ordovas JM; Schaefer EJ
    Atherosclerosis; 2005 Feb; 178(2):331-8. PubMed ID: 15694942
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of variants within seven candidate genes on statin treatment efficacy.
    Vrablík M; Hubáček JA; Dlouhá D; Lánská V; Rynekrová J; Zlatohlávek L; Prusíková M; Ceška R; Adámková V
    Physiol Res; 2012; 61(6):609-17. PubMed ID: 23098650
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of atorvastatin on serum vaspin levels in hypercholesterolemic patients with moderate cardiovascular risk.
    Kadoglou NP; Vrabas IS; Kapelouzou A; Lampropoulos S; Sailer N; Kostakis A; Liapis CD
    Regul Pept; 2011 Oct; 170(1-3):57-61. PubMed ID: 21640762
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment.
    Fiegenbaum M; da Silveira FR; Van der Sand CR; Van der Sand LC; Ferreira ME; Pires RC; Hutz MH
    Clin Pharmacol Ther; 2005 Nov; 78(5):551-8. PubMed ID: 16321621
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin.
    Stein E; Stender S; Mata P; Sager P; Ponsonnet D; Melani L; Lipka L; Suresh R; Maccubbin D; Veltri E;
    Am Heart J; 2004 Sep; 148(3):447-55. PubMed ID: 15389231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.
    Anderson JM; Cerda A; Hirata MH; Rodrigues AC; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
    J Clin Lipidol; 2014; 8(3):256-64. PubMed ID: 24793346
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association of ANRIL polymorphism (rs1333049:C>G) with myocardial infarction and its pharmacogenomic role in hypercholesterolemia.
    Ahmed W; Ali IS; Riaz M; Younas A; Sadeque A; Niazi AK; Niazi SH; Ali SH; Azam M; Qamar R
    Gene; 2013 Feb; 515(2):416-20. PubMed ID: 23266621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Interactions between CYP3A5*3 and POR*28 polymorphisms and lipid lowering response with atorvastatin.
    Wei KK; Zhang LR
    Clin Drug Investig; 2015 Sep; 35(9):583-91. PubMed ID: 26293521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYTAL study.
    Goldberg RB; Guyton JR; Mazzone T; Weinstock RS; Polis A; Edwards P; Tomassini JE; Tershakovec AM
    Mayo Clin Proc; 2006 Dec; 81(12):1579-88. PubMed ID: 17165637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 3'UTR/T polymorphism of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is associated with modified anti-platelet activity of atorvastatin in hypercholesterolemic subjects.
    Puccetti L; Pasqui AL; Pastorelli M; Ciani F; Palazzuoli A; Gioffrè W; Auteri A; Bruni F
    Atherosclerosis; 2005 Dec; 183(2):322-8. PubMed ID: 16285995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.